Literature DB >> 21623918

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.

Shane A Gangatharan, Dennis A Carney, Lynda J Campbell, H Miles Prince, Melita K Kenealy, John F Seymour.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21623918     DOI： 10.1111/j.1600-0609.2011.01653.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  2 in total

Review 1.  Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-05-28       Impact factor: 11.431

2.  Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan.

Authors:  Haruyuki Ishii; John F Seymour; Ryushi Tazawa; Yoshikazu Inoue; Naoyuki Uchida; Aya Nishida; Yoshihito Kogure; Takeshi Saraya; Keisuke Tomii; Toshinori Takada; Yuko Itoh; Masayuki Hojo; Toshio Ichiwata; Hajime Goto; Koh Nakata
Journal:  BMC Pulm Med       Date:  2014-03-05       Impact factor: 3.317
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.